Lung Cancer
Conditions
Interventions
Intervention:apatinib
Sponsors
The Second People's Hospital of Yibin
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years; 2. ECOG score: 0-2; 3. The histopathologic or cytopathologic diagnosed IIIB or IV non-central lung squamous carcinoma ,including patients with predominantly squamous cell tumours ( i.e. >50% of squamous cells in the sample used for histological diagnosisby a pathologist); 4. At least one measurable lesions, and distance great vessels > 5 mm (in accordance with the requirements of RECIST 1.1 the measurable lesions spiral CT scan length to diameter 10 mm or swollen lymph nodes or short diameter 15 mm or higher); 5. After treatment failure of chemotherapy of patients with advanced lung squamous carcinoma; 6. Patients who are unwilling to undergo first-line chemotherapy after first diagnosis or unwilling to continue to undergo chemotherapy; 7. The blood routine examination should accord with a standard (no blood transfusion and adjuvant therapies within 14 days, unused and other hematopoietic stimulating factor (g-csf) correct): HB 80 g/L or higher; the ANC acuity 1.5*10^9/L; PLT acuity 80*10^9/L; 8. Biochemical examination must be in accordance with the following criteria: TBIL 45 ml/min; 9. Women of childbearing age should be carried out in the group of 7 days before the pregnancy test (serum), and the resul; 10. Signed and dated informed consent. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure.
Exclusion criteria
Exclusion criteria: 1. Imaging (CT or MRI) shows signs of tumor invasion of large vessels, such as tumors that are completely close, wrapping or invading the lumen of the large vessels (such as the superior pulmonary artery or superior vena cava); 2. Radiological evidence suggests that there is empty or necrotic tumor; 3. Patients with EGFR, ALK or ROS1 gene sensitive mutations; 4. People with high blood pressure and antihypertensive drug therapy can not drop to normal range (systolic blood pressure = 140 mmHg, diastolic blood pressure = 90 mmHg); 5. Always suffer from severe cardiovascular disease: II magnitude of myocardial ischemia and myocardial infarction, poor control of cardiac arrhythmias (including QTc interphase male 450, female 470 ms or ms or higher); According to NYHA standard; 6. III~IV cardiac insufficiency, or heart colour to exceed revealed left ventricular ejection fraction (LVEF) 1.5, APTT ULN > 1.5), with bleeding tendency; 10. Patients who have significant effects on oral drug absorption (e.g., inability to swallow, frequent vomiting, etc); 11. The urine protein in patients with positive (+ 2 or more urinary protein detection, or 24 hours urinary protein quantitative > 1.0 g); 12. Other anti-angiogenic drugs (such as endostatin, bevacizumab) have been used within last 1 month; 13. Suffering from other untreated malignant tumors; 14. Pregnant or lactating women; 15. HIV positive, HCV positive, or RPR positive; 16. Patients with hepatitis B surface antigen (HBsAg) positive and peripheral blood of hepatitis B virus deoxyribonucleic acid (HBV DNA) titer over 1 * 103 copies /L; 17. Patients with contraindications, according to the drug manual; 18. Patients who are participating in other clinical trials; 19. Researchers think that patients don't suitable for this test.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS;Safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| ORR;DCR;OS; | — |
Countries
China
Contacts
Public ContactJia Yuming
The Second People's Hospital of Yibin
Outcome results
None listed